Neoadjuvant Therapy

Cross-source consensus on Neoadjuvant Therapy from 1 sources and 4 claims.

1 sources · 4 claims

Uses

In NEO-ERA-01, adjuvant capecitabine plus adebrelimab continues for six months after resection. — Neoadjuvant hepatic arterial infusion chemotherapy (HAIC) with GEMOX and lenvatinib in combination with adebrelimab for resectable high-risk recurrent intrahepatic cholangiocarcinoma (ICC): study protocol of the NEO-ERA-01 feasibility trial
Neoadjuvant therapy aims to eliminate micrometastases, downstage tumors, improve R0 resection probability, and reduce postoperative recurrence. — Neoadjuvant hepatic arterial infusion chemotherapy (HAIC) with GEMOX and lenvatinib in combination with adebrelimab for resectable high-risk recurrent intrahepatic cholangiocarcinoma (ICC): study protocol of the NEO-ERA-01 feasibility trial
Neoadjuvant therapy is indicated for technically resectable tumors that carry high-risk features for recurrence. — Neoadjuvant hepatic arterial infusion chemotherapy (HAIC) with GEMOX and lenvatinib in combination with adebrelimab for resectable high-risk recurrent intrahepatic cholangiocarcinoma (ICC): study protocol of the NEO-ERA-01 feasibility trial
A propensity score-matched analysis suggested improved overall survival for resectable high-risk ICC patients receiving neoadjuvant chemotherapy. — Neoadjuvant hepatic arterial infusion chemotherapy (HAIC) with GEMOX and lenvatinib in combination with adebrelimab for resectable high-risk recurrent intrahepatic cholangiocarcinoma (ICC): study protocol of the NEO-ERA-01 feasibility trial